arrow
P

Peter B. Jones

University of Cambridge
H指数:139
被引数:8.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neural correlates of peripheral inflammation in individuals with first-episode schizophrenia

首发精神分裂症患者外周炎症的神经相关性

2026-10-070
OAAI
Policy and public health implications for mental health after the COVID-19 pandemic

新型冠状病毒肺炎大流行后对精神卫生的政策和公共卫生影响

2026-01-210
PRE
Characterising negative symptoms in schizophrenia: CHANSS study protocol

精神分裂症阴性症状的表征:CHANSS研究方案

2025-11-060
OAAI
Polygenic and Polyenvironment Interplay in Schizophrenia-Spectrum Disorder and Affective Psychosis; the EUGEI First Episode Study

精神分裂症谱系障碍和情感性精神病中的多基因和多环境相互作用; EUGEI第一集研究

2024-12-101
OAAI
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

在eu-gei病例对照和英国Biobank研究中,精神分裂症遗传负荷和大量使用大麻对精神病风险的影响

2024-12-060
OAAI
Cannabis use and cognitive biases in people with first-episode psychosis and their siblings
2024-11-220
OAAI
The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

多基因风险评分和儿童逆境对首发精神病的跨诊断症状维度的影响: 精神病情感途径的证据

2024-10-260
OAAI
Methylomic signature of current cannabis use in two first-episode psychosis cohorts

在两个首发精神病队列中当前使用大麻的甲基特征

2024-10-160
OAAI
Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT)

首发精神病治疗抵抗风险的临床预测模型的开发和初步评估: 精神分裂症对治疗抵抗的预测 (精神)

2024-08-051
PRE